KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income towards Parent Company: 2014-2024

Historic Income towards Parent Company for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$408.0 million.

  • CRISPR Therapeutics AG's Income towards Parent Company fell 23.82% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$530.0 million, marking a year-over-year decrease of 96.03%. This contributed to the annual value of -$408.0 million for FY2024, which is 121.25% down from last year.
  • As of FY2024, CRISPR Therapeutics AG's Income towards Parent Company stood at -$408.0 million, which was down 121.25% from -$184.4 million recorded in FY2023.
  • CRISPR Therapeutics AG's 5-year Income towards Parent Company high stood at $377.7 million for FY2021, and its period low was -$652.5 million during FY2022.
  • Over the past 3 years, CRISPR Therapeutics AG's median Income towards Parent Company value was -$408.0 million (recorded in 2024), while the average stood at -$415.0 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Income towards Parent Company slumped by 633.48% in 2020, and later skyrocketed by 205.94% in 2021.
  • CRISPR Therapeutics AG's Income towards Parent Company (Yearly) stood at -$356.5 million in 2020, then soared by 205.94% to $377.7 million in 2021, then plummeted by 272.78% to -$652.5 million in 2022, then surged by 71.74% to -$184.4 million in 2023, then slumped by 121.25% to -$408.0 million in 2024.